메뉴 건너뛰기




Volumn 28, Issue 2, 2014, Pages 269-277

IMWG consensus on risk stratification in multiple myeloma

(14)  Chng, W J a,b,c   Dispenzieri, A d   Chim, C S e   Fonseca, R f   Goldschmidt, H g   Lentzsch, S h   Munshi, N i   Palumbo, A j   Miguel, J S k   Sonneveld, P l   Cavo, M m   Usmani, S n   Durie, B Gm o   Avet Loiseau, H p  


Author keywords

biomakers; prognosis; treatment

Indexed keywords

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84893782640     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.247     Document Type: Review
Times cited : (513)

References (67)
  • 1
    • 79961027391 scopus 로고    scopus 로고
    • Treatment of multiple myeloma
    • Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 479-491
    • Rajkumar, S.V.1
  • 3
    • 76249096571 scopus 로고    scopus 로고
    • How i treat multiple myeloma in younger patients
    • Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114: 5436-5443.
    • (2009) Blood , vol.114 , pp. 5436-5443
    • Stewart, A.K.1    Richardson, P.G.2    San-Miguel, J.F.3
  • 4
    • 34547660308 scopus 로고    scopus 로고
    • Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    • Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
    • (2007) Cancer Cell , vol.12 , pp. 131-144
    • Keats, J.J.1    Fonseca, R.2    Chesi, M.3    Schop, R.4    Baker, A.5    Chng, W.J.6
  • 5
    • 80855156719 scopus 로고    scopus 로고
    • Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    • Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
    • (2011) Blood , vol.118 , pp. 4771-4779
    • Zhu, Y.X.1    Braggio, E.2    Shi, C.X.3    Bruins, L.A.4    Schmidt, J.E.5    Van Wier, S.6
  • 6
    • 80055066620 scopus 로고    scopus 로고
    • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
    • Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118: 4519-4529.
    • (2011) Blood , vol.118 , pp. 4519-4529
    • Palumbo, A.1    Bringhen, S.2    Ludwig, H.3    Dimopoulos, M.A.4    Blade, J.5    Mateos, M.V.6
  • 7
    • 77951923656 scopus 로고    scopus 로고
    • Survival and years of life lost in different age cohorts of patients with multiple myeloma
    • Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28: 1599-1605.
    • (2010) J Clin Oncol , vol.28 , pp. 1599-1605
    • Ludwig, H.1    Bolejack, V.2    Crowley, J.3    Blade, J.4    Miguel, J.S.5    Kyle, R.A.6
  • 8
    • 84863919796 scopus 로고    scopus 로고
    • Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival
    • Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30: 1949-1952.
    • (2012) J Clin Oncol , vol.30 , pp. 1949-1952
    • Avet-Loiseau, H.1    Attal, M.2    Campion, L.3    Caillot, D.4    Hulin, C.5    Marit, G.6
  • 9
    • 0027164309 scopus 로고
    • Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
    • Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
    • (1993) Blood , vol.81 , pp. 3382-3387
    • Greipp, P.R.1    Lust, J.A.2    O'Fallon, W.M.3    Katzmann, J.A.4    Witzig, T.E.5    Kyle, R.A.6
  • 10
    • 27144493396 scopus 로고    scopus 로고
    • Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    • Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276-2279.
    • (2005) Blood , vol.106 , pp. 2276-2279
    • Nowakowski, G.S.1    Witzig, T.E.2    Dingli, D.3    Tracz, M.J.4    Gertz, M.A.5    Lacy, M.Q.6
  • 11
    • 0032055938 scopus 로고    scopus 로고
    • Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group
    • Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501-2507.
    • (1998) Blood , vol.91 , pp. 2501-2507
    • Greipp, P.R.1    Leong, T.2    Bennett, J.M.3    Gaillard, J.P.4    Klein, B.5    Stewart, J.A.6
  • 12
    • 79956039754 scopus 로고    scopus 로고
    • Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
    • Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117: 4696-4700.
    • (2011) Blood , vol.117 , pp. 4696-4700
    • Munshi, N.C.1    Anderson, K.C.2    Bergsagel, P.L.3    Shaughnessy, J.4    Palumbo, A.5    Durie, B.6
  • 13
    • 74049162897 scopus 로고    scopus 로고
    • International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
    • Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
    • (2009) Leukemia , vol.23 , pp. 2210-2221
    • Fonseca, R.1    Bergsagel, P.L.2    Drach, J.3    Shaughnessy, J.4    Gutierrez, N.5    Stewart, A.K.6
  • 14
    • 36849014859 scopus 로고    scopus 로고
    • Role of genetics in prognostication in myeloma
    • Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007; 20: 625-635.
    • (2007) Best Pract Res Clin Haematol , vol.20 , pp. 625-635
    • Avet-Loiseau, H.1
  • 15
    • 0038142356 scopus 로고    scopus 로고
    • Clinical and biologic implications of recurrent genomic aberrations in myeloma
    • Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
    • (2003) Blood , vol.101 , pp. 4569-4575
    • Fonseca, R.1    Blood, E.2    Rue, M.3    Harrington, D.4    Oken, M.M.5    Kyle, R.A.6
  • 16
    • 79951504474 scopus 로고    scopus 로고
    • Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor?
    • Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117: 2009-2011.
    • (2011) Blood , vol.117 , pp. 2009-2011
    • Avet-Loiseau, H.1    Malard, F.2    Campion, L.3    Magrangeas, F.4    Sebban, C.5    Lioure, B.6
  • 17
    • 84856706335 scopus 로고    scopus 로고
    • A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial
    • Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.
    • (2012) Leukemia , vol.26 , pp. 349-355
    • Boyd, K.D.1    Ross, F.M.2    Chiecchio, L.3    Dagrada, G.P.4    Konn, Z.J.5    Tapper, W.J.6
  • 18
    • 33748196399 scopus 로고    scopus 로고
    • Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
    • Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724-1732.
    • (2006) Blood , vol.108 , pp. 1724-1732
    • Hanamura, I.1    Stewart, J.P.2    Huang, Y.3    Zhan, F.4    Santra, M.5    Sawyer, J.R.6
  • 19
    • 33750327901 scopus 로고    scopus 로고
    • Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
    • Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034-2040.
    • (2006) Leukemia , vol.20 , pp. 2034-2040
    • Fonseca, R.1    Van Wier, S.A.2    Chng, W.J.3    Ketterling, R.4    Lacy, M.Q.5    Dispenzieri, A.6
  • 20
    • 33847378314 scopus 로고    scopus 로고
    • Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome
    • Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
    • (2007) Blood , vol.109 , pp. 3489-3495
    • Avet-Loiseau, H.1    Attal, M.2    Moreau, P.3    Charbonnel, C.4    Garban, F.5    Hulin, C.6
  • 21
    • 84895803630 scopus 로고    scopus 로고
    • Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients
    • e-pub ahead of print 29 July 2013; doi: 10.1038/leu.2013.225
    • Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2013; e-pub ahead of print 29 July 2013; doi: 10.1038/leu.2013.225.
    • (2013) Leukemia
    • Hebraud, B.1    Leleu, X.2    Lauwers-Cances, V.3    Roussel, M.4    Caillot, D.5    Marit, G.6
  • 22
    • 77950949924 scopus 로고    scopus 로고
    • Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma
    • Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833-842.
    • (2010) Leukemia , vol.24 , pp. 833-842
    • Chng, W.J.1    Gertz, M.A.2    Chung, T.H.3    Van Wier, S.4    Keats, J.J.5    Baker, A.6
  • 23
    • 84055212016 scopus 로고    scopus 로고
    • Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
    • Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776-7784.
    • (2011) Clin Cancer Res , vol.17 , pp. 7776-7784
    • Boyd, K.D.1    Ross, F.M.2    Walker, B.A.3    Wardell, C.P.4    Tapper, W.J.5    Chiecchio, L.6
  • 24
    • 34548138922 scopus 로고    scopus 로고
    • Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    • Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007; 21: 2020-2024.
    • (2007) Leukemia , vol.21 , pp. 2020-2024
    • Moreau, P.1    Attal, M.2    Garban, F.3    Hulin, C.4    Facon, T.5    Marit, G.6
  • 25
    • 84863290659 scopus 로고    scopus 로고
    • Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics
    • Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
    • (2012) Blood , vol.119 , pp. 2100-2105
    • Kumar, S.1    Fonseca, R.2    Ketterling, R.P.3    Dispenzieri, A.4    Lacy, M.Q.5    Gertz, M.A.6
  • 26
    • 78650735473 scopus 로고    scopus 로고
    • The microarray quality control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
    • Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010; 28: 827-838.
    • (2010) Nat Biotechnol , vol.28 , pp. 827-838
    • Shi, L.1    Campbell, G.2    Jones, W.D.3    Campagne, F.4    Wen, Z.5    Walker, S.J.6
  • 27
    • 82555194601 scopus 로고    scopus 로고
    • Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine
    • Meissner T, Seckinger A, Reme T, Hielscher T, Mohler T, Neben K et al. Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 2011; 17: 7240-7247.
    • (2011) Clin Cancer Res , vol.17 , pp. 7240-7247
    • Meissner, T.1    Seckinger, A.2    Reme, T.3    Hielscher, T.4    Mohler, T.5    Neben, K.6
  • 28
    • 0016804136 scopus 로고
    • A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
    • Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
    • (1975) Cancer , vol.36 , pp. 842-854
    • Durie, B.G.1    Salmon, S.E.2
  • 30
    • 84872076977 scopus 로고    scopus 로고
    • Standard and novel imaging methods for multiple myeloma: Correlates with prognostic laboratory variables including gene expression profiling data
    • Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 2013; 98: 71-78.
    • (2013) Haematologica , vol.98 , pp. 71-78
    • Waheed, S.1    Mitchell, A.2    Usmani, S.3    Epstein, J.4    Yaccoby, S.5    Nair, B.6
  • 31
    • 84875209671 scopus 로고    scopus 로고
    • Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project
    • Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013; 27: 711-717.
    • (2013) Leukemia , vol.27 , pp. 711-717
    • Avet-Loiseau, H.1    Durie, B.G.2    Cavo, M.3    Attal, M.4    Gutierrez, N.5    Haessler, J.6
  • 32
    • 77954477911 scopus 로고    scopus 로고
    • Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
    • Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150-1157.
    • (2010) Haematologica , vol.95 , pp. 1150-1157
    • Neben, K.1    Jauch, A.2    Bertsch, U.3    Heiss, C.4    Hielscher, T.5    Seckinger, A.6
  • 33
    • 57449109100 scopus 로고    scopus 로고
    • Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival
    • Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
    • (2008) J Clin Oncol , vol.26 , pp. 5775-5782
    • Lahuerta, J.J.1    Mateos, M.V.2    Martinez-Lopez, J.3    Rosinol, L.4    Sureda, A.5    De La Rubia, J.6
  • 34
    • 37249040444 scopus 로고    scopus 로고
    • Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    • Haessler J, Shaughnessy Jr. JD, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-7079.
    • (2007) Clin Cancer Res , vol.13 , pp. 7073-7079
    • Haessler, J.1    Shaughnessy Jr., J.D.2    Zhan, F.3    Crowley, J.4    Epstein, J.5    Van Rhee, F.6
  • 35
    • 70349320472 scopus 로고    scopus 로고
    • Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols
    • Hoering A, Crowley J, Shaughnessy Jr JD, Hollmig K, Alsayed Y, Szymonifka J et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114: 1299-1305.
    • (2009) Blood , vol.114 , pp. 1299-1305
    • Hoering, A.1    Crowley, J.2    Shaughnessy Jr., J.D.3    Hollmig, K.4    Alsayed, Y.5    Szymonifka, J.6
  • 36
    • 48249127515 scopus 로고    scopus 로고
    • Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
    • Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355-359.
    • (2008) Cancer , vol.113 , pp. 355-359
    • Barlogie, B.1    Anaissie, E.2    Haessler, J.3    Van Rhee, F.4    Pineda-Roman, M.5    Hollmig, K.6
  • 37
    • 73349126431 scopus 로고    scopus 로고
    • Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: Long-term analysis of the IFM 99-02 and 99-04 Trials
    • Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009; 27: 5720-5726.
    • (2009) J Clin Oncol , vol.27 , pp. 5720-5726
    • Harousseau, J.L.1    Avet-Loiseau, H.2    Attal, M.3    Charbonnel, C.4    Garban, F.5    Hulin, C.6
  • 38
    • 79953126259 scopus 로고    scopus 로고
    • Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
    • Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011; 117: 3041-3044.
    • (2011) Blood , vol.117 , pp. 3041-3044
    • Moreau, P.1    Attal, M.2    Pegourie, B.3    Planche, L.4    Hulin, C.5    Facon, T.6
  • 39
    • 79953078844 scopus 로고    scopus 로고
    • Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients
    • Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025-3031.
    • (2011) Blood , vol.117 , pp. 3025-3031
    • Gay, F.1    Larocca, A.2    Wijermans, P.3    Cavallo, F.4    Rossi, D.5    Schaafsma, R.6
  • 40
    • 59449099316 scopus 로고    scopus 로고
    • Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
    • Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017-4023.
    • (2008) Blood , vol.112 , pp. 4017-4023
    • Paiva, B.1    Vidriales, M.B.2    Cervero, J.3    Mateo, G.4    Perez, J.J.5    Montalban, M.A.6
  • 41
    • 84856086596 scopus 로고    scopus 로고
    • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
    • Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691.
    • (2012) Blood , vol.119 , pp. 687-691
    • Paiva, B.1    Gutierrez, N.C.2    Rosinol, L.3    Vidriales, M.B.4    Montalban, M.A.5    Martinez-Lopez, J.6
  • 42
    • 77951625298 scopus 로고    scopus 로고
    • Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
    • Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
    • (2010) J Clin Oncol , vol.28 , pp. 2077-2084
    • Ladetto, M.1    Pagliano, G.2    Ferrero, S.3    Cavallo, F.4    Drandi, D.5    Santo, L.6
  • 43
    • 84873737833 scopus 로고    scopus 로고
    • Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma
    • Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 398-404.
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 398-404
    • Kroger, N.1    Badbaran, A.2    Zabelina, T.3    Ayuk, F.4    Wolschke, C.5    Alchalby, H.6
  • 44
    • 84868559447 scopus 로고    scopus 로고
    • Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
    • Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012; 97: 1757-1760.
    • (2012) Haematologica , vol.97 , pp. 1757-1760
    • Hillengass, J.1    Ayyaz, S.2    Kilk, K.3    Weber, M.A.4    Hielscher, T.5    Shah, R.6
  • 45
    • 82955189267 scopus 로고    scopus 로고
    • Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
    • Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118: 5989-5995.
    • (2011) Blood , vol.118 , pp. 5989-5995
    • Zamagni, E.1    Patriarca, F.2    Nanni, C.3    Zannetti, B.4    Englaro, E.5    Pezzi, A.6
  • 48
    • 78650303860 scopus 로고    scopus 로고
    • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study
    • Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085.
    • (2010) Lancet , vol.376 , pp. 2075-2085
    • Cavo, M.1    Tacchetti, P.2    Patriarca, F.3    Petrucci, M.T.4    Pantani, L.5    Galli, M.6
  • 49
    • 84865171981 scopus 로고    scopus 로고
    • Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 Trial
    • Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 Trial. J Clin Oncol 2013; 30: 2946-2955.
    • (2013) J Clin Oncol , vol.30 , pp. 2946-2955
    • Sonneveld, P.1    Schmidt-Wolf, I.G.2    Van Der Holt, B.3    El Jarari, L.4    Bertsch, U.5    Salwender, H.6
  • 50
    • 72949085546 scopus 로고    scopus 로고
    • Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    • Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
    • (2009) Mayo Clin Proc , vol.84 , pp. 1095-1110
    • Kumar, S.K.1    Mikhael, J.R.2    Buadi, F.K.3    Dingli, D.4    Dispenzieri, A.5    Fonseca, R.6
  • 51
    • 84893787279 scopus 로고    scopus 로고
    • Impact of bortezomib incorporated into autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: An integrated analysis of 1894 patients enrolled in four European Phase 3 Studies
    • Abstract 749
    • Cavo M, Sonneveld P, Moreau P, Blade J, Goldschmidt H, San Miguel J et al. Impact of Bortezomib Incorporated Into Autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: an integrated analysis of 1894 patients enrolled in four European Phase 3 Studies. Blood 2012; 120: Abstract 749.
    • (2012) Blood , vol.120
    • Cavo, M.1    Sonneveld, P.2    Moreau, P.3    Blade, J.4    Goldschmidt, H.5    San Miguel, J.6
  • 52
    • 78049501226 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    • Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.
    • (2010) J Clin Oncol , vol.28 , pp. 4630-4634
    • Avet-Loiseau, H.1    Leleu, X.2    Roussel, M.3    Moreau, P.4    Guerin-Charbonnel, C.5    Caillot, D.6
  • 53
    • 70350001654 scopus 로고    scopus 로고
    • TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
    • Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009; 147: 347-351.
    • (2009) Br J Haematol , vol.147 , pp. 347-351
    • Shaughnessy, J.D.1    Zhou, Y.2    Haessler, J.3    Van Rhee, F.4    Anaissie, E.5    Nair, B.6
  • 54
    • 84856278440 scopus 로고    scopus 로고
    • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    • Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940-948.
    • (2012) Blood , vol.119 , pp. 940-948
    • Neben, K.1    Lokhorst, H.M.2    Jauch, A.3    Bertsch, U.4    Hielscher, T.5    Van Der Holt, B.6
  • 55
    • 84862937267 scopus 로고    scopus 로고
    • The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
    • Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119: 7-15.
    • (2012) Blood , vol.119 , pp. 7-15
    • Morgan, G.J.1    Gregory, W.M.2    Davies, F.E.3    Bell, S.E.4    Szubert, A.J.5    Brown, J.M.6
  • 56
    • 80053111637 scopus 로고    scopus 로고
    • Approach to the treatment of multiple myeloma: A clash of philosophies
    • Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011; 118: 3205-3211.
    • (2011) Blood , vol.118 , pp. 3205-3211
    • Rajkumar, S.V.1    Gahrton, G.2    Bergsagel, P.L.3
  • 58
    • 84864561961 scopus 로고    scopus 로고
    • Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    • Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
    • (2012) Blood , vol.120 , pp. 1060-1066
    • Egan, J.B.1    Shi, C.X.2    Tembe, W.3    Christoforides, A.4    Kurdoglu, A.5    Sinari, S.6
  • 60
    • 33947217497 scopus 로고    scopus 로고
    • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    • Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2006; 109: 2276-2284.
    • (2006) Blood , vol.109 , pp. 2276-2284
    • Shaughnessy Jr., J.D.1    Zhan, F.2    Burington, B.E.3    Huang, Y.4    Colla, S.5    Hanamura, I.6
  • 61
    • 54249092519 scopus 로고    scopus 로고
    • Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myelome
    • Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008; 26: 4798-4805.
    • (2008) J Clin Oncol , vol.26 , pp. 4798-4805
    • Decaux, O.1    Lode, L.2    Magrangeas, F.3    Charbonnel, C.4    Gouraud, W.5    Jezequel, P.6
  • 62
    • 38949203768 scopus 로고    scopus 로고
    • The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    • Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111: 1603-1609.
    • (2008) Blood , vol.111 , pp. 1603-1609
    • Chng, W.J.1    Braggio, E.2    Mulligan, G.3    Bryant, B.4    Remstein, E.5    Valdez, R.6
  • 63
    • 77949686098 scopus 로고    scopus 로고
    • Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
    • Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010; 16: 1856-1864.
    • (2010) Clin Cancer Res , vol.16 , pp. 1856-1864
    • Dickens, N.J.1    Walker, B.A.2    Leone, P.E.3    Johnson, D.C.4    Brito, J.L.5    Zeisig, A.6
  • 64
    • 79953892192 scopus 로고    scopus 로고
    • A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
    • Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
    • (2011) Haematologica , vol.96 , pp. 574-582
    • Moreaux, J.1    Klein, B.2    Bataille, R.3    Descamps, G.4    Maiga, S.5    Hose, D.6
  • 65
    • 78650981539 scopus 로고    scopus 로고
    • Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
    • Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011; 96: 87-95.
    • (2011) Haematologica , vol.96 , pp. 87-95
    • Hose, D.1    Reme, T.2    Hielscher, T.3    Moreaux, J.4    Messner, T.5    Seckinger, A.6
  • 67
    • 84879266916 scopus 로고    scopus 로고
    • A novel measure of chromosome instability can account for prognostic difference in multiple myeloma
    • Chung TH, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One 2013; 8: e66361.
    • (2013) PLoS One , vol.8
    • Chung, T.H.1    Mulligan, G.2    Fonseca, R.3    Chng, W.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.